NFKB1 and bacterial urinary tract infection: The findings revealed lower levels of NF-κB phosphorylation in TLF-II-treated mice than in both UTI and LVFX mice (Figures 5B, D), implying that TLF-II can inhibit NF-κB activation and exert anti-inflammatory effects.